Rucaparib camsylate is the salt form of Rucaparib, a PARP inhibitor used to treat cancers with BRCA1/2 mutations. It is mainly indicated for ovarian and metastatic prostate cancers, especially in cases with defective DNA repair. The drug works by inhibiting PARP enzymes, preventing cancer cells from repairing their DNA. It is grouped under the following drug class(es): Antineoplastic agents and PARP Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include rucaparib camphorsulfonate, CO-338 and Rubraca. Its PubChem CID is 121490161.
Rucaparib camsylate
| CAS No | 1859053-21-6 |
|---|---|
| Molecular Formula | C29H34FN3O5S |
| Molecular Weight | 555.7 g/mol |
| Synonyms | [(1S,4R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rucaparib camsylate is the salt form of Rucaparib, a PARP inhibitor used to treat cancers with BRCA1/2 mutations. It is mainly indicated for ovarian and metastatic prostate cancers, especially in cases with defective DNA repair.
The listed CAS number is 1859053-21-6.
The listed molecular formula is C29H34FN3O5S.
The listed molecular weight is 555.7 g/mol.
[(1S,4R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one.
The source lists rucaparib camphorsulfonate, CO-338 and Rubraca.